KRAS and colorectal cancer: This synergism is clinically validated in the KRYSTAL-1 trial: while adagrasib (KRAS G12C inhibitor) monotherapy yielded 16% ORR in colorectal cancer, combination with cetuximab increased ORR to 46% (Ou et al., 2022; Negrao et al., 2023).